NCCN临床实践指南:外阴癌(2024.V4)
1.指南来源(Guide Source):
NCCN临床实践指南:外阴癌 V4.2024.发布已获NCCN肿瘤学临床实践指南(NCCN指南®)许可。©2024美国国家综合癌症网络公司.保留所有权利。未经NCCN明确的书面许可,不得出于任何目的以任何形式复制NCCN指南®和文中的插图。要查看NCCN指南的最新完整版本,请访问NCCN.org。NCCN指南是一项持续进行的工作,可能会随着新的重要数据的出现而不断完善。
2.免责声明(Disclaimers):
NCCN对其内容、使用或应用不做任何形式的担保,并否认以任何方式对其应用或使用承担任何责任。
在下载本篇指南前,请先您详细阅读并同意以下协议:
NCCN内容不得用于商业目的,以及NCCN作为NCCN内容的许可方,不作任何陈述或保证,并明确否认NCCN指南适用于任何特定患者的护理或治疗,任何医院、寻求使用《NCCN指南》治疗患者的临床医生或其他医疗服务提供者(“提供者”)应根据特定患者护理或治疗的具体临床情况做出独立的医疗判断,NCCN不建议、推荐或认可任何提供者(无论是否与被许可方相关)进行任何有偿或无偿的医疗治疗、咨询或服务,也不应因被许可方建议、推荐或认可任何此类提供者的作为或不作为而直接或间接承担责任。详见《NCCN最终用户许可协议》
3.专家名单(Staff):
*Nadeem R. Abu-Rustum, MD Ω/Chair Memorial Sloan Kettering Cancer Center
*Catheryn M. Yashar, MD §/Vice Chair UC San Diego Moores Cancer Center
Kristin Bradley, MD § University of Wisconsin Carbone Cancer Center
Rebecca Brooks, MD Ω UC Davis Comprehensive Cancer Center
Susana M. Campos, MD, MPH, MS † Dana-Farber/Brigham and Women’s Cancer Center
Junzo Chino, MD § Duke Cancer Institute
Hye Sook Chon, MD Ω Moffitt Cancer Center
Christina Chu, MD Ω Fox Chase Cancer Center
David Cohn, MD Ω The Ohio State University Comprehensive Cancer Center -James Cancer Hospital and Solove Research Institute
Marta Ann Crispens, MD Ω Vanderbilt-Ingram Cancer Center
Shari Damast, MD § Yale Cancer Center/Smilow Cancer Hospital
Elisabeth Diver, MD Ω Stanford Cancer Institute
Christine M. Fisher, MD, MPH § University of Colorado Cancer Center
Peter Frederick, MD Ω Roswell Park Comprehensive Cancer Center
David K. Gaffney, MD, PhD § Huntsman Cancer Institute at the University of Utah
Robert Giuntoli II, MD Ω Abramson Cancer Center at the University of Pennsylvania
Ernest Han, MD, PhD Ω City of Hope National Medical Center
Brooke Howitt, MD ≠ Stanford Cancer Institute
Warner K. Huh, MD Ω O'Neal Comprehensive Cancer Center at UAB
Jayanthi Lea, MD Ω UT Southwestern Simmons Comprehensive Cancer Center
Andrea Mariani, MD Ω Mayo Clinic Cancer Center
David Mutch, MD Ω Siteman Cancer Center at Barnes- Jewish Hospital and Washington University School of Medicine
Larissa Nekhlyudov, MD, MPH Þ Dana-Farber/Brigham and Women’s Cancer Center
*Nadeem R. Abu-Rustum, MD Ω/Chair Memorial Sloan Kettering Cancer Center
*Catheryn M. Yashar, MD §/Vice Chair UC San Diego Moores Cancer Center
Kristin Bradley, MD § University of Wisconsin Carbone Cancer Center
Rebecca Brooks, MD Ω UC Davis Comprehensive Cancer Center
Susana M. Campos, MD, MPH, MS † Dana-Farber/Brigham and Women’s Cancer Center
Junzo Chino, MD § Duke Cancer Institute
Hye Sook Chon, MD Ω Moffitt Cancer Center
Christina Chu, MD Ω Fox Chase Cancer Center
David Cohn, MD Ω The Ohio State University Comprehensive Cancer Center -James Cancer Hospital and Solove Research Institute
Marta Ann Crispens, MD Ω Vanderbilt-Ingram Cancer Center
Shari Damast, MD § Yale Cancer Center/Smilow Cancer Hospital
Elisabeth Diver, MD Ω Stanford Cancer Institute
Mirna Podoll, MD ≠Vanderbilt-Ingram Cancer Center
Steven W. Remmenga, MD Ω Fred & Pamela Buffett Cancer Center
R. Kevin Reynolds, MD Ω University of Michigan Rogel Cancer Center
Ritu Salani, MD, MBA Ω UCLA Jonsson Comprehensive Cancer Center
Rachel Sisodia, MD Ω Massachusetts General Hospital Cancer Center
Pamela Soliman, MD, MPH Ω The University of Texas MD Anderson Cancer Center
Edward Tanner, MD Ω Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Stefanie Ueda, MD Ω UCSF Helen Diller Family Comprehensive Cancer Center
Renata Urban, MD Ω Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
Stephanie L. Wethington, MD, MSc Ω The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Emily Wyse ¥ Patient Advocate
Kristine Zanotti, MD Ω Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
NCCN Nicole McMillian, MS Angela Motter, PhD
4.临床试验(Clinical Trials):
NCCN认为任何癌症患者都可以在临床试验中得到最佳治疗,因此特别鼓励患者参与临床试验。 寻找NCCN成员组:https://www.nccn.org/home/member-institutions
5.NCCN对证据和共识分类( NCCN Categories of Evidence and Consensus):
推荐均为2A类,除非另有说明,请参见下表:
|
NCCN 对证据和共识的分类 |
1类 |
基于高水平证据,NCCN一致认为此项治疗合理 |
2A类 |
基于低水平证据,NCCN一致认为此项治疗合理 |
2B类 |
基于低水平证据,NCCN基本认为此项治疗合理 |
3类 |
基于任何水平证据,NCCN对此项治疗是否合理存在重大分歧 |
6.NCCN首选分类( NCCN Categories of Preference):
所有建议均视为合理,请参见下表:
|
NCCN 优先使用分类 |
首选干预方法 |
若合适,可负担,则基于疗效、安全性和证据更优的干预方法 |
推荐的其他干预方法 |
其他繁育方法可能疗效较低,毒性更多,或一句的数据不太成熟;或者具有相似疗效,但费用明显较高 |
某些情况下有用 |
其他干预方法可能会用于选定的患者人群(根据推荐类型定义) |
|
|
部分内容仅可在
临床指南app 查看下载
收藏
分享
NCCN作为美国21家顶尖肿瘤中心组成的非营利性学术组织,其宗旨是为在全球范围内提高肿瘤服务水平,造福肿瘤患者。其制订的《NCCN肿瘤学临床实践指南》不仅是美国肿瘤领域临床决策的标准,也已成为全球肿瘤临床实践中应用最为广泛的指南,在中国也得到了广大肿瘤医生的认可与青睐。